Abbott Ireland Diagnostics Division - Global Center of Excellence for In Vitro Diagnostics Manufactu

📢 Manufacturing Excellence (2024-2026):
   Abbott Ireland Diagnostics Division operates two world-class manufacturing sites in Ireland. The Sligo facility, Abbott's second-largest diagnostics plant globally, has expanded eight times since 1994 and now spans nearly 170,000 square feet. The Longford facility, opened in 2004, covers 200,000 square feet on a 27-acre greenfield site and manufactures over 50 diagnostic reagent products. The Longford site received the Abbott Global Large Quality Plant of the Year Award in 2023 and the prestigious Shingo Prize in 2016 for operational excellence. As of January 2026, Abbott continues actively recruiting for diagnostic manufacturing roles in Sligo.

Company Overview (Updated April 2026)

Abbott Ireland Diagnostics Division is the diagnostic manufacturing division of Abbott Laboratories (NYSE: ABT) in Ireland, operating as part of Abbott's global Core Diagnostics business. The division manages two major manufacturing facilities located in Sligo (Northwest Ireland) and Longford (Midlands Ireland), which collectively produce a comprehensive portfolio of in vitro diagnostic (IVD) reagents and tests for laboratories, hospitals, and blood banks worldwide.

Abbott first established its presence in Ireland in 1946 and today employs approximately 6,000 people across 10 sites nationwide, making Abbott one of Ireland's largest multinational employers and the multinational with the most manufacturing locations in the country. The diagnostics operations represent a cornerstone of Abbott's Irish manufacturing footprint, supporting the company's position as a global leader in laboratory diagnostics with around 70,000 institutional customers in more than 100 countries.

Corporate History & Facility Development

- 1994: Abbott established its first Irish diagnostics manufacturing facility at Finisklin Business Park, Sligo, initially focused on blood-screening products and reagents

- 2004: Expansion continued with the opening of a second diagnostics facility in Longford, located at Lisnamuck on the outskirts of Longford town

- December 2005: First product from Longford—Architect® TSH (Thyroid Stimulating Hormone)—launched successfully

- 2016: Longford facility awarded the prestigious Shingo Prize from the University of Utah and the Shingo Institute for Operational Excellence

- 2017: Sligo facility achieved ISO 50001 Energy Management certification, subsequently reducing CO2 emissions by 40% and energy costs by 36%

- 2023: Longford facility awarded Abbott Global Large Quality Plant of the Year

- 2024-Present: Continued manufacturing of Alinity platform reagents and accessory products; active FDA reporting and quality monitoring ongoing

Manufacturing Facilities

Sligo Facility - Core Diagnostics

Address: Finisklin Business Park, Sligo, F91 VY44, Ireland
   Phone: +353 (0)71 915 6200
   Size: Nearly 170,000 square feet over a 9-acre site (expanded 8 times since inception)
   Status: Abbott's second-largest diagnostics manufacturing facility worldwide

Products Manufactured:

- Infectious Disease Assays: Detection assays for Hepatitis B, Rubella, and Cytomegalovirus (CMV) associated with congenital disorders

- Oncology Assays: Measurement of key blood proteins indicative of prostate cancer, liver cancer, and various other tumors

- Traumatic Brain Injury Assays: Biomarker tests for brain injury assessment

- Therapeutic Drug Monitoring: Products for monitoring drug concentrations in the body

- Alinity Platform Accessory Reagents: Instrument accessory reagents including wash buffers, trigger solutions, pre-trigger solutions, and chemistry-based reagents for daily operation of Abbott's Alinity and Architect diagnostic analyzers

- Process and Product Innovation Laboratories: Established in Sligo to support development of pioneering new diagnostic products

Quality & Environmental Certifications:

- ISO 50001 Energy Management System (implemented with €6,000 cost,<1 year="" payback="">

Longford Facility - Core Diagnostics

Address: Lisnamuck, Longford, Ireland
   Phone: +353 (0)43 333 1000
   Size: 200,000 square feet on a 27-acre greenfield site
   Status: Zero-landfill site with multiple global operational excellence awards

Products Manufactured (50+ Assays):

- Cardiac Diagnostics: High-Sensitivity Troponin-I (hs-TnI) blood test for heart attack evaluation; particularly beneficial for women who often produce lower troponin levels during cardiac events

- Thyroid Function: Architect® TSH and related thyroid assays

- Fertility and Pregnancy: Reproductive hormone assays

- Renal Function: Kidney disease diagnostic markers

- Metabolic Disease: Metabolic and endocrine diagnostic panels

Awards & Certifications:

- Shingo Prize (2016) for operational excellence

- Abbott Global Environment, Health, Safety and Energy Plant of the Year (2009, 2011, 2013, 2015; runner-up 2007, 2008, 2010)

- Abbott Global Large Quality Plant of the Year (2023)

- IMDA Med Tech Company of the Year (2015)

- ISO 14001 Environmental Management System

- OHSAS 18001 Occupational Health and Safety Management System

- ISO 50001 Energy Management System

- Zero-landfill certified facility

Regulatory Compliance & Global Registrations

China NMPA (National Medical Products Administration):

The Sligo facility maintains active import medical device filings in china, including:

- 国械备20170599号 (2017-06-19): Alinity Trigger Solution (氢氧化钠溶液) - 975mL/bottle, provides alkaline environment for chemiluminescence reactions; product validity extended to 18 months (updated 2020-01-20)

- 国械备20170602号 (2017-06-19): Alinity i-series Concentrated Wash Buffer (1.5M磷酸盐缓冲溶液) - 2.0L/bottle, for sample and tubing washing on Alinity i analyzers

- 国械备20170601号 (2017-06-19): Alinity Pre-Trigger Solution (含1.32%过氧化氢酸性溶液) - 975mL/bottle, provides reaction environment for chemiluminescence

FDA (United States):

Active adverse event reporting and product monitoring through FDA MAUDE database (2024-2025 reports for Alinity Cyclosporine Reagent Kit and Alinity Anti-TPO Reagent Kit, confirming ongoing US market supply and quality surveillance)

Global Quality Standards:

- All products manufactured to highest quality standards regulated by FDA and ISO    - Full compliance with EU In Vitro Diagnostic Regulation (IVDR)    - Quality Policy: "To improve healthcare by providing high-quality, safe and effective diagnostic products"

Products & Technology Platforms

Supported Diagnostic Platforms:

- Alinity Series: Immunoassay (Alinity i), clinical chemistry, transfusion, and hematology applications

- Architect Series: Integrated systems for immunoassay and clinical chemistry

Key Product Categories:

- Blood screening reagents for transfusion medicine    - Infectious disease serology assays    - Oncology tumor marker assays    - Cardiac biomarker tests (High-Sensitivity Troponin-I)    - Thyroid function panels    - Fertility and pregnancy hormone assays    - Therapeutic drug monitoring reagents    - Traumatic brain injury biomarkers    - Instrument accessory reagents (wash buffers, trigger/pre-trigger solutions, diluents)

Strategic Importance

Global Supply Hub: The Irish diagnostics facilities serve as critical manufacturing centers within Abbott's global supply chain, exporting diagnostic reagents and tests to laboratories and hospitals in over 100 countries.

Innovation Center: The Sligo site's Process and Product Innovation Laboratories support development of next-generation diagnostic assays and platform technologies.

Operational Excellence: Both facilities exemplify world-class manufacturing standards, with Longford achieving the Shingo Prize and Sligo implementing award-winning energy management systems.

Employment: Significant contributor to regional employment in the Northwest and Midlands of Ireland, with ongoing recruitment for engineering, quality, laboratory technician, and manufacturing roles.

Corporate Information

Division Name: Abbott Ireland Diagnostics Division (Core Diagnostics)

- Parent Company: Abbott Laboratories (NYSE: ABT)

- Sligo Site Established: 1994

- Longford Site Established: 2004 (first product 2005)

- Total Abbott Ireland Employees: ~6,000 across 10 sites (as of 2024)

- Website: www.ie.abbott

Contact Information

Sligo Facility:
   Abbott Core Diagnostics
   Finisklin Business Park
   Sligo, F91 VY44
   Ireland
   Tel: +353 (0)71 915 6200

Longford Facility:
   Abbott Ireland Diagnostic Division
   Lisnamuck
   Longford, Ireland
   Tel: +353 (0)43 333 1000

Corporate:
   Abbott Ireland
   Block G, Cherrywood Business Park
   Loughlinstown, Dublin 18 D18 T3Y1
   Ireland
   Tel: 353 (0) 1 7781000

Keywords: Abbott Ireland Diagnostics Division, Abbott Core Diagnostics, Sligo diagnostics, Longford diagnostics, Finisklin Business Park, Lisnamuck, Alinity reagents, Architect assays, High-Sensitivity Troponin-I, infectious disease assays, oncology diagnostics, blood screening, diagnostic reagents manufacturing, Shingo Prize, ISO 50001, zero landfill, Abbott Laboratories Ireland, IVD manufacturing, chemiluminescence, wash buffer, trigger solution, NMPA China, FDA MAUDE